Press Releases for MITI

Press Releases
Micromet, Inc. Reports Second Quarter 2009 Financial Results
Micromet Closes $80.5 Million Public Offering of Common Stock
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
Micromet Announces Pricing of Public Offering of Common Stock
Micromet Announces Public Offering of Common Stock
Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
Micromet Added to Russell 3000 Index
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Micromet, Inc. Reports First Quarter 2009 Financial Results
Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Micromet, Inc. (MITI) President and Chief Executive Officer to Ring The NASDAQ Stock Market Closing Bell
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
Micromet to Host an Investor Meeting and Ring the Closing Bell of the NASDAQ Stock Exchange on April 24, 2009 in New York City
Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Micromet to Present at the Cowen Health Care Conference on March 17, 2009
Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results on March 12, 2009
Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
New Data Published in Immunobiology Describe Mode of Action of BiTE Antibody MT110
Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
Micromet Key Events for 2009
Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non-Hodgkin's Lymphoma
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
Micromet to Present at the RBC Capital Markets Healthcare Conference
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
Micromet Expands Committed Equity Financing Facility to $75 Million
Micromet Added to NASDAQ Biotechnology Index
Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab at American Society of Hematology Annual Meeting
Micromet, Inc. Reports Third Quarter 2008 Financial Results
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
Micromet Closes $40 Million Private Equity Placement
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
Micromet, Inc. Reports Second Quarter 2008 Financial Results
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas - May 26 2008 10:31PM
Micromet, Inc. Reports First Quarter 2008 Financial Results - Jun 2 2008 1:05AM
Micromet, Inc. to Host Conference Call and Webcast to Discuss First Quarter 2008 Financial Results - Jun 2 2008 1:04AM
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma